Table of Contents
Share At:
Listen Article:
0:00 /
0:00
Trastuzumab Injection for Cancer Treatment
Table of Contents
Those who are seeking to find out information on Trastuzumab Injection might be interested in learning about a variety of aspects of this drug, including its side effects, its bioavailability and the market for it.
Treatment of Cancers with High Levels of the Her2 Protein in Trastuzumab Injection
HER2 is a type of protein that plays a crucial role in the growth and survival of normal cells. In tumours, HER2 overexpression leads to malignant transformation of the cell. This protein is overexpressed in many types of cancer including ovarian, breast, gastric, and prostate cancers.
Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the HER2 protein. It blocks tyrosine kinase activity in the cell, which interrupts a signaling pathway within the cell. It also induces apoptosis in breast cancer cells. It was approved by the FDA in 1998 for the treatment of patients with breast cancer. However, it has limited therapeutic efficacy as a single agent. It is sometimes combined with other drugs to avoid its drawbacks.
What are the Precautions to be Taken with Trastuzumab Injection?
Taking Trastuzumab injections can be an effective treatment for certain types of cancer, such as stomach cancer.
Trastuzumab is a monoclonal antibody that attaches to specific proteins, known as HER2, in cancer cells. This causes the cancer cells to die. Trastuzumab is usually used in conjunction with other cancer medicines. It is also used in some breast cancer patients who have not responded to other medicines.
When used with chemotherapy, it is important to monitor all patients and take precautions when using this injection.
What is Bioavailability of Trastuzumab Injection?
Typical pharmacokinetic profiles for three regimens of intravenous (IV) or subcutaneous (SC) trastuzumab in HER2-positive early breast cancer (EBC) patients were compared. Using a two-compartment model, the pharmacokinetic (PK) parameters were derived. These include maximum serum concentration (MSC), maximum serum concentration-time (Ct), AUC0-21 days, Ctrough, and the relative magnitude of the random effect on central volume (RCV). The estimated bioavailability of s.c. trastuzumab was 77 percent, or 1.45 percent of the reference i.v. regimen (RSE).
In the phase I/Ib study, the pharmacokinetics of a fixed 600-mg SC dose were compared with those of an IV regimen. The pharmacokinetics of IV and SC regimens were similar. However, the concentrations of the IV regimen were significantly higher. This may be due to the fact that the intravenous regimen was administered in a shorter time period.
Several significant studies have been conducted to assess the bioavailability and preference of subcutaneous and intravenous administration of trastuzumab for early HER2-positive breast cancer.
The study was a multicentre randomised phase III study. Patients were enrolled by their treating physician. Initially, the dose was given in four 1.0 mg injections, which increased over time. Trastuzumab is a standard of care for early HER2-positive breast cancer. In the GAIN-2 study, patients were randomized to either intravenous (IV) or subcutaneous (SC) administration. In the per-protocol set, 30 patients were investigated. The plasma concentration-time profiles showed a significant difference in the bioavailability of the subcutaneous versus the IV site.
Market Analysis of Trastuzumab Injection
Increasing prevalence of cancer and changing lifestyle are expected to drive the global trastuzumab injection market in the coming years. Increasing availability of biosimilars will further reduce biologic costs. Moreover, increased R&D activities will also offer lucrative growth opportunities.
Global market for trastuzumab injection is estimated to reach US$ 1.3 billion in 2022. A survey conducted by has estimated the market to grow at a CAGR of 24.5% in the next decade.
The rising prevalence of breast cancer has urged many market players to invest in the research and development of new products. The current pipeline of breast cancer drugs is strong. The rising healthcare expenditure in Asia Pacific is also expected to drive the market. However, Europe is expected to retain its second position in the market.
The Bottom Line
Breast cancer that has advanced to other body areas is treated with trastuzumab injections, either concurrently with other treatments or after other medications have been tried. Injections of trastuzumab reduce the possibility of breast cancer coming back. It functions by preventing the spread of cancer cells.
